Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation of the efficacy and safety of immune checkpoint inhibitor treatment in recurrent/advanced endometrial cancer patients who have failed platinum-based chemotherapy, as well as the effect of combined treatment with trastuzumab in patients with HER2/neu-positive endometrial cancer. Additionally, the guideline assessed the efficacy and safety of omitting lymph node dissection in low-risk endometrial cancer patients, investigated the effect of sentinel lymph node mapping in early-stage endometrial cancer surgery, addressed the outcome of chemoradiation therapy as a postoperative treatment in patients with advanced (stage III-IVA) endometrial cancer, and explored the impact of initial treatment with immune checkpoint inhibitors on survival in patients with advanced or recurrent endometrial cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10948989 | PMC |
| http://dx.doi.org/10.3802/jgo.2024.35.e45 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Interpretable Machine Learning for Proteomics-Based Subtyping and Tumor Mutational Burden Prediction in Endometrial Cancer.
Proteomics Clin Appl
September 2025
AIBioMed Research Group, Taipei Medical University, Taipei, Taiwan.
Background: Endometrial carcinoma (EC) represents a significant clinical challenge due to its pronounced molecular heterogeneity, directly influencing prognosis and therapeutic responses. Accurate classification of molecular subtypes (CNV-high, CNV-low, MSI-H, POLE) and precise tumor mutational burden (TMB) assessment is crucial for guiding personalized therapeutic interventions. Integrating proteomics data with advanced machine learning (ML) techniques offers a promising strategy for achieving precise, clinically actionable classification and biomarker discovery in EC.
View Article and Find Full Text PDFOmitting adjuvant therapy in POLE-mutated endometrial carcinoma with cervical stromal invasion: are we moving too fast?
Int J Gynecol Cancer
August 2025
Radiation Department, A.O. S. Croce e Carle Teaching Hospital, Cuneo CN, Italy.
Oligoclonal expansion of IgG+ B cells along with Tfh cell response is associated with a better outcome in endometrial cancer.
Int Immunol
September 2025
Department of Immunology, Graduate School of Medicine, Kyoto University.
B cells play a critical role in tumor immunity, with their presence associated with improved prognosis in various cancers, including endometrial cancer (EC). However, the nature of the B cell response within the tumor microenvironment (TME) remains incompletely understood. In this study, we conducted single-cell analyses of B cells and CD4+ T cells in the TME of EC.
View Article and Find Full Text PDFRevisiting the paradigm: Asymptomatic high-grade endometrial cancer diagnosis is not associated with improved outcomes.
Eur J Surg Oncol
September 2025
Barzilai University Medical Center, Ashkelon, Israel; Faculty of Health Sciences, Ben-Gurion University of Negev, Beer-Sheva, Israel.
Objective: To compare the survival of women with high grade endometrial cancer between asymptomatic and women presenting bleeding symptoms.
Design: An Israel Gynecologic Oncology Group multi-center retrospective cohort study.
Methods: The study included women who underwent surgery for high-grade endometrial cancer.
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53.
Transl Oncol
September 2025
The University of New Mexico, Albuquerque, NM, USA. Electronic address:
Ovarian and endometrial cancers frequently harbor a mutation in the tumor suppressor gene TP53, which occurs in over 90 % of ovarian cancers and in the most aggressive endometrial cancers. The normal tumor suppressive functions of p53 are disrupted, resulting in unregulated cell growth and therapeutic resistance to standard treatments including chemotherapy and PARP inhibitors. Hence, a novel therapeutic strategy is urgently needed for p53 mutant gynecologic cancers, and we propose that converting mutant p53 to a wild type conformation and restoring its tumor suppressive functions has the potential to greatly improve treatment.
View Article and Find Full Text PDF